New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical ...

Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use ...

Early-stage studies presented at ESMO reported promising activity for several experimental treatments for advanced prostate cancer. Johnson & Johnson’s oral JNJ-6143 produced substantial PSA declines ...

The UAE is turning into a proving ground for clinical AI, and the newest example sits in a pathology lab in Abu Dhabi.

Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...

Miguel Zugman։ Exploring JNJ-6143 as a First-in-Class RIPTAC in Heavily Pretreated Prostate Cancer / Benjamin Garmezy, cancer, ESMO2026, ESMO26, JNJ-6143, ...

Darolutamide Plus ADT and Radiotherapy in Very High-Risk Prostate Cancer / cancer, cancer care, Cancer research, cancer treatment, ...

University of Michigan researchers report that the molecular glue RPT04402 stabilizes the trimeric tumor suppressor PP2A, ...

A drug at the heart of Johnson & Johnson's $3 billion takeover of Halda last year, JNJ-6143, has shown promise in an ...

Columnist Graham Couch grades the Spartans' performance at UCLA on Saturday — offense, defense, special teams, coaching and ...

Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week ...

Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases ...